Glucose is an important energy source for our cancer-killing T cells. In kidney tumors, however, poor nutrient conditions often disrupt T cell metabolism and inhibit their anti-cancer activity. Dr. Beckermann is characterizing how exactly the tumor environment perturbs T cell metabolism. Then, using patients’ cells and mouse models, she’s developing approaches to support T cells and restore their normal metabolism. The insights she uncovers might then suggest ways to target and improve the effectiveness of these anti-cancer T cells in immunotherapies for patients.
Vanderbilt University | Breast Cancer, Kidney Cancer, Lung Cancer, Melanoma | 2016 | Jeffrey Rathmell, Ph.D.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
July is Sarcoma Awareness Month. As a rare and difficult-to-treat form of cancer, effective drug treatments are urgently needed and immunotherapy for sarcoma shows promise.
Dr. Joan Levy, director of research at the Chordoma Foundation, discusses the current state of chordoma research and the recently launched partnership with CRI.